Merus
MRUS
Market cap $3.52B

51.60 USD

-1.09

2.07%

At close Oct 21, 4:00 PM EDT

After hours

51.60

+0.00

0.00%

1 day

-2.07%

5 days

-1.07%

1 month

8.02%

3 months

-7.49%

6 months

27.56%

Year to date

80.29%

1 year

148.55%

5 years

210.28%

About: Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Employees: 229

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

170% more call options, than puts

Call options by funds: $41.4M | Put options by funds: $15.4M

85% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 26

70% more capital invested

Capital invested by funds: $2.35B [Q1] → $3.99B (+$1.63B) [Q2]

64% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 44

36% more funds holding in top 10

Funds holding in top 10: 14 [Q1] → 19 (+5) [Q2]

14% more funds holding

Funds holding: 155 [Q1] → 177 (+22) [Q2]

11.49% more ownership

Funds ownership: 90.19% [Q1] → 101.68% (+11.49%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$67

30%

upside

Avg. target

$88

70%

upside

High target

$111

115%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Guggenheim	115%upside $111	Buy Maintained	1 Oct 2024
Needham Ami Fadia 57% 1-year accuracy 60 / 106 met price target	65%upside $85	Buy Maintained	5 Aug 2024
Canaccord Genuity John Newman 59% 1-year accuracy 13 / 22 met price target	30%upside $67	Buy Maintained	25 Jul 2024

See Analyst Rankings

Financial journalist opinion

Merus: Great European Oncology Developer, But Properly Valued

Merus NV has seen a significant increase in market cap from $852mn to $3.46bn in the past year. Merus is a leader in developing multispecific antibodies with promising lead candidates petosemtamab and zenocutuzumab targeting various cancers. Merus has strong financials, and partnerships with major companies like Gilead, Incyte, and Eli Lilly, but faces risks due to its current valuation and assumptions about pipeline success.

Merus: Great European Oncology Developer, But Properly Valued

Zacks Investment Research

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago.

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

Zacks Investment Research

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.

Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

Merus Announces Pricing of Upsized Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 1,132,500 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $400.2 million. All of the shares in the offering are to be sold by Merus.

Merus Announces Pricing of Upsized Public Offering of Common Shares

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET.

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Merus N.V. Announces Proposed Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Merus N.V. Announces Proposed Public Offering of Common Shares

See News Rankings

Charts implemented using Lightweight Charts™